<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03800108</url>
  </required_header>
  <id_info>
    <org_study_id>17-1350</org_study_id>
    <nct_id>NCT03800108</nct_id>
  </id_info>
  <brief_title>Stimulation Parameters and Non-motor Symptoms in PD Treated With DBS</brief_title>
  <acronym>FREQUENCY</acronym>
  <official_title>Stimulation Parameters and Non-motor Symptoms in PD Treated With DBS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Darlene Floden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the role of subthalamic nucleus (STN) stimulation location and frequency
      on a range of cognitive processes in Parkinson's patients who have undergone Deep Brain
      Stimulation (DBS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pre- and post- DBS implantation brain scans will be reviewed by the study team to see if
      patients' DBS settings can be personalized. If so, study subjects will undergo adjustments to
      their DBS settings and be asked to perform cognitive tests. Some patients will be asked to
      come back for a second visit for brain scans.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reaction time</measure>
    <time_frame>30-60 minutes after stimulation adjustment</time_frame>
    <description>Subjects will complete one or more measures of cognitive processing requiring speeded responses to stimuli. Changes in reaction time will be compared to 'off stimulation'</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Verbal Fluency</measure>
    <time_frame>30-60 minutes after stimulation adjustment</time_frame>
    <description>Change in the number words that patients generate to letter or semantic category cues will be compared to 'off stimulation'</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Finger tapping speed</measure>
    <time_frame>30-60 minutes after stimulation adjustment</time_frame>
    <description>Change in upper extremity speed (# of taps in 10 seconds) will be compared to 'off stimulation'</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>Personalized DBS adjustments</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Personalized DBS adjustments</intervention_name>
    <description>Individualized stimulation adjustments based on pre- and post- DBS implantation MRIs</description>
    <arm_group_label>Personalized DBS adjustments</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Between 40 and 70 years of age,

          2. Ability to provide informed consent,

          3. Clinical diagnosis of idiopathic Parkinson disease (PD) by a movement disorders
             neurologist,

          4. Disease duration of at least 4 years,

          5. Treated with bilateral STN DBS for at least 3 months prior to study enrollment.

        Exclusion Criteria:

          1. History of prior neurosurgical intervention for PD (e.g., DBS, thalamotomy,
             pallidotomy)

          2. History of other central nervous system disease (excluding migraine),

          3. Presence of active psychiatric symptoms meeting Diagnostic and Statistical Manual of
             Mental Disorders-4th Edition (DSM-IV) criteria for Axis-I disorder on formal
             psychiatric evaluation, with the exception of mild depression (Beck Depression
             Inventory-2 score below 19),

          4. Cognitive impairment meeting Diagnostic and Statistical Manual of Mental Disorders-4th
             Edition (DSM-IV) criteria for dementia on formal neuropsychological evaluation,

          5. Current alcohol or substance abuse,

          6. Lack of fluency in English which would invalidate cognitive testing,

          7. Hearing or visual impairment precluding cognitive testing.

             Exclusion criteria for Day 2 procedures:

          8. Inability to safely undergo MRI procedure (i.e., metal objects like prostheses,
             pacemakers)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darlene Floden, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julia Biars</last_name>
    <phone>216-445-4826</phone>
    <email>biarsj@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2019</study_first_posted>
  <last_update_submitted>July 17, 2019</last_update_submitted>
  <last_update_submitted_qc>July 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>The Cleveland Clinic</investigator_affiliation>
    <investigator_full_name>Darlene Floden</investigator_full_name>
    <investigator_title>Staff Neuropsychologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

